Academic Frontiers . . . Yang Xuejun team of Tianjin General Hospital found that the new drug ACT001 new mechanism to inhibit glioma growth Phase II clinical trial will be launched

Recently, Professor Yang Xuejun of Neurosurgery at Tianjin Medical University General Hospital team edged the team of Professor Michael Lim of Johns Hopkins University School of Medicine and members of the ORIGINAL research team of ACT001 University of Nankai Universityin the Biomedical Area 1 journal Theranostics (2018 IF: 8.063)published, the paper reported that the new drug ACT001, which is based in China, inhibits the transcription of the immune-checking molecule PD-L1 by targeting the phosphorylation of the transcription factor STAT3, which can inhibit the growth of GBM in mouse models and prolong the survival period of the lotus mice, which is expected to be converted to clinicalProfessor Yang Xuejun of Neurosurgery at Tianjin Medical University General Hospital is the author of the paper's newsletter, and the group members DrTong Luqing (Joint Training) and DrLi Jiabo are the first authors of the articleAccording to the outside of the front line, the original research of the new drug ACT001 in China's Phase II clinical trial, will soon start, and by Tianjin Medical University General Hospital Professor Yang Xuejun as the head of the generalOriginal link: https://
it is understood that glioblastoma (GBM) itself has considerable immunosuppressive characteristics, while current chemotherapy has limited lysing to improve patients' survival time while promoting GBM immunosuppressionDue to difficulty in passing through limitations such as blood-brain barrier, PD-1 monoantigens and other drugs that can significantly reverse tumor immunosuppressive tumors in other tumors are compromised in Phase III clinical trials of GBMTherefore, the drug to reverse brain GBM immunosuppression needs to be developedACT001 is a new anti-tumor drug developed by Professor Chen Yue of Nankai University School of Pharmacy in China, which retains the drug activity group of PTL, but overcomes the disadvantages of PTL instability and poor water solubilityAt present, ACT001 for relapsed GBM Phase II clinical trials, has been the United States FDA and the Chinese Drug Administration licenseIn the study, the researchers found that STAT3 molecules played an important role in GBM treatment for resistance and immunosuppressionACT001 inhibits the expression of GBM cell STAT3 phosphorylation and PD-L1In-depth study found that phosphorylation STAT3 can be combined to the pD-L1 starter to facilitate the transcription of PD-L1; The immune-sounding mouse in situ brain GBM model further confirmed that oral 400mg/kg/d ACT001 can significantly inhibit the expression of p-STAT3 and PD-L1 in brain GBM, and significantly prolong the survival of the mother the study demonstrated in in vivo and external experiments that ACT001 was able to target the expression of p-STAT3 and PD-L1 to reverse the immune suppression of the brain GBM given that brain GBM is a significant heterogeneous disease, this result suggests that patients with high expression of p-STAT3 may benefit from ACT001 treatment In addition, ACT001 and the current GBM radiation chemotherapy combined application may be able to counteract the immunosuppression of radiation chemotherapy, resulting in synergies references: Tong L, Li J, Li Q, Wang X, Medikonda R, Zhao T, Li T, Ma H, Yi L, Liu P, Xie Y, Choi J, Yu S, Lin Y, Dong J, Huang Q, Jin Lim, M, Yang X ACT001 Theranostics 2020; 10(13):5943-5956 doi: 10.7150/thno.41498 Communication Author professor yang Xuejun, doctoral doctor, professor, doctoral doctoral , doctoral doctoral research, who has been engaged in neurosurgery, teaching and scientific research for 29 years, is currently the Deputy Director of Neurosurgery, Director of Neurosurgery, Director of Neurosurgery, Director of Neurosurgery and Neurosurgery, Brain Tumor and Brain Function Research Institute, Tianjin Institute of Research, and Clinical Research Director, Tianjin Institute of Research PI, Director of the Global Center for Clinical Innovation in Neuroglioma Adaptation, Director of the National Clinical Research Center for Neurological Disorders, Academic: WFNS Member, Executive Member and Secretary of the Eurasian Academy of Neurosurgery , Vice Chairman of the Professional Committee of glioma stoma of the Chinese Physicians Association, Chairman of the China Glioma Collaboration Group, Beijing-Tianjin-Jin-Jin-Jin(Jin-Meng) Glioma Alliance, Chairman of the Panel of Neuro-Oncology of Beijing Oncology Society, Vice Editor of China Journal of Modern Neurological Diseases and Glioma, and other 10 professional magazine editorial board sits or reviewers; Leader; Winner of the 2016 Wang Loyal Chinese Neurosurgery Academic Achievement Award; first "China Physicians' Day" Tianjin Medical University "Clinical Teaching Contribution Award"; presided over more than 10 national key research and development projects, the National Natural Science Foundation and provincial-level topics, published more than 180 Papers in Chinese and English, participated in nearly 30 monographs, and participated in 9 guidelines or consensus-writing in the field of neurosurgery , the first author of the paper, Tong Luqing, M.D., surgery (neurosurgery) major, in the direction of cerebral glioma research Tianjin Medical University 2015 Grade Shubo Lian, 2018.10-2020.06 National Public School of Medicine, Johns Hopkins University School of Medicine, United States He was engaged in the study of immune-related prognostic markers for glioma and act001 anti-glioma mechanism During his tenure, Dr Shuo served as secretary of the Party branch, secretary of the branch of the League and other positions, and has won many honors such as outstanding graduate students, outstanding Communist Youth League members and outstanding Communist Party members of Tianjin Medical University To the first or co-first author published 5 SCI papers, the cumulative impact factor of 19.6 points, the declaration of utility model patents 1, participate in the translation of 1 first author Li Jiabo, 2019 Ph.D student of Tianjin Medical University, surgery (neurosurgery) major, mainly in the field of glioma During his postgraduate studies, he was devoted to the study of the mechanism of ACT001 anti-glioma stem cells and immunosuppressive microenvironments and the study of immune-related prognostic markers for glioma During the period, the first or co-author published 4 Chinese and English papers, including 2 SCI papers, and also participated in the publication of 7 SCI papers As a major participant, he participated in a number of projects on the surface of the National Natural Science Foundation of China, key projects of the Tianjin Science and Technology Commission, and basic research cooperation projects in Beijing, Tianjin and Hebei Source: